Novartis says has no intention of buying Actavis
ZURICH (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday.
"We have no intention to pursue them," spokesman Eric Althoff said in response to inquiries.
The Wall Street Journal earlier reported that Novartis - which operates a large generics business called Sandoz - was considering whether to enter the fray, after Actavis rebuffed separate takeover offers from Valeant Pharmaceuticals International Inc and Mylan Inc.
SAN FRANCISCO - Apple Inc has approved another $30 billion in share buybacks till the end of 2015 and authorized a rarely seen seven-for-one stock split, addressing calls to share more of its cash hoard while broadening the stock's appeal to individual investors.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.